Obesity and Diabetes
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
Published in Obesity and Diabetes Week, September 10th, 2007
Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) ("companies") announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007. Pfizer's DGAT- 1 discovery program includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes. The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals Corporation in June 2006, including a pre-clinical compound (known as PF-04415060 or BAY 74-4113) originally discovered by Bayer.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity
Professor Looks To Gardening To Combat Child Obesity - Obesity and Diabetes
AASM encourages those student-athletes at risk for developing OSA to visit a sleep clinic - Obesity and Diabetes
Circulating fats kill transplanted pancreas cells, study shows - Obesity and Diabetes
New Imaging Technique Reveals Fatty Hearts in Pre-diabetics - Obesity and Diabetes
Researchers Identify A Role for Glucose-Sensing Neurons in Type 2 Diabetes - Obesity and Diabetes
Understanding How Fat Cells in Obese People Work - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
